Publications by authors named "Benjamin Lockshin"

Claim this Profile
R
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical Trial.
Melinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, Neal Bhatia, Michael Bukhalo, Benjamin Lockshin

JAMA Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Review of the Safety and Efficacy of Deucravacitinib for Plaque Psoriasis: An Expert Consensus Panel.
Milaan Shah, Joshua Burshtein, Danny Zakria, Erin Boh, Michael Cameron, Benjamin Lockshin

J Drugs Dermatol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Descriptive, Post Hoc Analysis of Efficacy and Safety of Risankizumab in Diverse Racial and Ethnic Patient Populations With Moderate-to-Severe Psoriasis.
Andrew F Alexis, Melinda Gooderham, Shawn G Kwatra, Ahmad Amin, Susan Taylor, Benjamin Lockshin

Dermatol Ther (Heidelb)· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluating the clinical utility of the Atopic Dermatitis Control Tool: measurement properties and agreement between patients' responses and clinicians' impressions of atopic dermatitis control.
Eric L Simpson, Laurent Eckert, Abhijit Gadkari, T Michelle Brown, Peter A Lio, Benjamin Lockshin

Br J Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Efficacy and Safety of Bimekizumab for Plaque Psoriasis: An Expert Consensus Panel.
Joshua Burshtein, Milaan Shah, Danny Zakria, Benjamin Lockshin, Jeff Crowley

Dermatol Ther (Heidelb)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinically Meaningful Responses to Dupilumab Among Children Aged 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis who did Not Achieve Clear or Almost Clear Skin According to the Investigator's Global Assessment: A Post Hoc Analysis of a Phase 3 Trial.
Michael J Cork, Benjamin Lockshin, Andreas Pinter, Zhen Chen, Brad Shumel

Acta Derm Venereol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
Amy S Paller, Jonathan I Silverberg, Michael J Cork, Emma Guttman-Yassky, Benjamin Lockshin

JAMA Dermatol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
Amy S Paller, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Peter D Arkwright, Benjamin Lockshin

Paediatr Drugs· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical Trial.
Joel M Gelfand, Daniel B Shin, April W Armstrong, Stephen K Tyring, Andrew Blauvelt, Benjamin N Lockshin

JAMA Dermatol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.
Benjamin Lockshin, Ryan W Harrison, Robert R McLean, Margaux M Crabtree, Bruce W Konicek

Dermatol Ther (Heidelb)· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
Amy S Paller, Eric L Simpson, Elaine C Siegfried, Michael J Cork, Andreas Wollenberg, Benjamin Lockshin

Lancet· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
Andrew Blauvelt, Kenneth B Gordon, Patricia Lee, Jerry Bagel, Howard Sofen, Benjamin Lockshin

J Dermatolog Treat· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Retrospective Cohort Analysis of Treatment Patterns Over 1 Year in Patients with Psoriasis Treated with Ixekizumab or Guselkumab.
Andrew Blauvelt, Russel Burge, Gaia Gallo, Bridget Charbonneau, William Malatestinic, Benjamin Lockshin

Dermatol Ther (Heidelb)· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex Differences in Subclinical Coronary Atherosclerosis in Psoriasis by Coronary Computed Tomography Angiography.
Meron Teklu, Wunan Zhou, Promita Kapoor, Nidhi Patel, Martin P Playford, Benjamin Lockshin

JACC Cardiovasc Imaging· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: The Corrona Psoriasis Registry.
Benjamin Lockshin, Angel Cronin, Ryan W Harrison, Robert R McLean, Laura Anatale-Tardiff

Dermatol Ther· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A case report of uveitis secondary to dupilumab treatment for atopic dermatitis.
Marissa Ayasse, Benjamin Lockshin, Brian K Do, Rachel Kaiser, Jonathan I Silverberg

JAAD Case Rep· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of machine learning to determine top predictors of noncalcified coronary burden in psoriasis: An observational cohort study.
Eric Munger, Harry Choi, Amit K Dey, Youssef A Elnabawi, Jacob W Groenendyk, Benjamin Lockshin

J Am Acad Dermatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic inflammation in psoriasis promotes visceral adiposity associated with noncalcified coronary burden over time.
Aparna Sajja, Khaled M Abdelrahman, Aarthi S Reddy, Amit K Dey, Domingo E Uceda, Benjamin Lockshin

JCI Insight· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Therapies for Psoriasis: Clinical and Economic Comparisons.
Albert Marchetti, Tina Bhutani, Benjamin Lockshin, Daniel M Siegel, Frederick Behringer

J Drugs Dermatol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Placebo-Controlled Trial of Secukinumab on Aortic Vascular Inflammation in Moderate-to-Severe Plaque Psoriasis (VIP-S).
Joel M Gelfand, Daniel B Shin, Kristina Callis Duffin, April W Armstrong, Andrew Blauvelt, Benjamin N Lockshin

J Invest Dermatol· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Plaque Psoriasis With an Excimer Laser Utilizing an Optimal Therapeutic UVB Dose Protocol.
Quinn Thibodeaux, Kristen Beck, Benjamin N Lockshin, Neal Bhatia, Ethan Levin

J Drugs Dermatol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eruptive collagenomas associated with adalimumab treatment of juvenile rheumatoid arthritis.
Leonard C Sperling, Benjamin Lockshin, Thomas Darling

J Cutan Pathol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis: A Phase 3 Randomized Clinical Trial.
Eric L Simpson, Amy S Paller, Elaine C Siegfried, Mark Boguniewicz, Lawrence Sher, Benjamin Lockshin

JAMA Dermatol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis in the United States: A Multicenter Observational Study.
Phillip J Mease, Clive Liu, Evan Siegel, Heather Richmond, Meijing Wu, Benjamin Lockshin

Am J Clin Dermatol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apremilast mechanism of efficacy in systemic-naive patients with moderate plaque psoriasis: Pharmacodynamic results from the UNVEIL study.
Bruce Strober, Ali Alikhan, Benjamin Lockshin, Rebecca Shi, Joshua Cirulli

J Dermatol Sci· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis